Search In this Thesis
   Search In this Thesis  
العنوان
Lymphangiogenesis in oral squamous cell carcinoma, correlation with VEGF-C expression and lymph node metastasis : Immunohistochemical and RT-PCR study :
الناشر
Manar Abdulwaniss Mohammed Abdulaziz ,
المؤلف
Manar Abdulwaniss Mohammed Abdulaziz
هيئة الاعداد
باحث / Manar Abdulwaniss Mohammed Abdulaziz
مشرف / Amina Kamel
مشرف / Dalia Hussein El-Rouby
مشرف / Olfat Shaker
تاريخ النشر
2016
عدد الصفحات
167P. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
Dentistry (miscellaneous)
تاريخ الإجازة
22/10/2017
مكان الإجازة
جامعة القاهرة - الفم والأسنان - Oral and Maxillofacial Pathology
الفهرس
Only 14 pages are availabe for public view

from 187

from 187

Abstract

Background: Oral squamous cell carcinoma (OSCC) is the most common oral malignancy that preferentially spreads to the cervical lymph node which, when involved, complicates the anticancer therapy and threatens the patient life. It was suggested that lymph node (LN) metastasis may be facilitated by lymphangiogenesis. VEGF C is one of the most important lymphangiogenic inducers that promotes the lymphatic vessels growth and supports the survival of adult lymphatic endothelial cells. Methods: Lymphatic vessels density (LVD) and LV morphometry were digitally evaluated using D2-40. The expression of VEGF C was also assessed using immunohistochemistry (IHC) and real time polymerase chain reaction (RT-PCR) in 6 normal oral mucosa and 72 cases of OSCC. The correlation between LVD and LV morphometry, VEGF C and lymph node metastasis were done. Results: A positive cytoplasmic expression of VEGF C was detected in both epithelial and connective tissue cells in 97% of OSCC while all normal tissues negatively reacted. A greater expression of VEGF C was associated with larger and more dilated LV and lymph node metastasis but not with LVD. Conclusion: VEGF C is actively involved in the invasion and metastasis of OSCC via inducing morphological changes in LV. VEGF C, being almost absent in normal tissue, may be a promising target for anticancer therapy